

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: GUT et al.  
Title: METHOD FOR HLA TYPING  
Appl. No.: Unassigned (US National Stage of PCT/IB2004/004115)  
International Filing Date: 11/26/2004  
371(c) Date:  
Examiner: Unassigned  
Art Unit: Unassigned  
Confirmation Number: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

**RELEVANCE OF EACH DOCUMENT**

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. Copies of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date May 25, 2006

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

By Michael D. Kummel  
Reg. No. 32,904,1

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

10/580646

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

APPROPRIATE TO 25 MAY 2006  
Complete if known

Substitute for form 1449B/PTO				Application Number		Unassigned	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Filing Date		11/26/2004	
Date Submitted: May 25, 2006				First Named Inventor		Glynne Ivo GUT	
(use as many sheets as necessary)				Group Art Unit		Unassigned	
Sheet 1 of 1				Examiner Name		Unassigned	
				Attorney Docket Number		065691-0447	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,451,512	A	APPLE et al.	09/19/1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A2	WO	00/65088	A	Amersham Pharm. Biotech. AB	11/02/2000		
	A3	WO	02/08462	A	Lechner et al.	01/31/2002		
	A4	WO	02/18659	A	Haplogen LLC	03/07/2002		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	PASTINEN et al., "Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation," Clinical Chemistry, American Association for Clinical Chemistry, vol. 42, no. 9, 1996, pp. 1391-1397.	
	A6	WORRALL et al., "Allele-specific HLA-DR typing by mass spectrometry: an alternative to hybridization-based typing methods," Analytical Chemistry, November 1, 2000, vol. 72, no. 21, pp. 5233-5238.	
	A7	LEUSHNER et al., "Automated mass spectroscopic platform for high throughput DR Beta typing," Human Immunology, vol. 61, no. Supplement 2, 2000, p. S126.	
	A8	TOST et al., "Genotyping single nucleotide polymorphisms by mass spectrometry," Mass Spectrometry Reviews, vol. 21, no. 6, November 2002, pp. 388-418.	
	A9	TOST et al., "Molecular haplotyping at high throughput," Nucleic Acids Research, October 1, 2002, vol. 30, no. 19, p. e96.	
	A10	SAUER et al., "Extension of the good assay for genotyping single nucleotide polymorphisms by matrix-assisted laser desorption/ionization mass spectrometry," Rapid Communications in Mass Spectrometry, vol. 17, no. 12, May 9, 2003, pp. 1265-1272.	
	A11	SAUER et al., "Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry," Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, December 25, 2002, vol. 782, no. 1-2, pp. 73-87.	
	A12	ROZEMULLER, "Reference panels for sequence based typing: Selection criteria for HLA-A and HLA-B," 2000, retrieved from the Internet: URL: <a href="http://www.ihwg.org/tmanual/TMcontents.htm">http://www.ihwg.org/tmanual/TMcontents.htm</a> , retrieved on 07/05/2004.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH\_1607445.1